

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES


Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
14 June 2001 (14.06.2001)


PCT

(10) International Publication Number
WO 01/41742 A2

- (51) International Patent Classification⁷: A61K 9/22, A61P 31/18
- (21) International Application Number: PCT/US00/33542
- (22) International Filing Date: 8 December 2000 (08.12.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/169,883 9 December 1999 (09.12.1999) US
- (71) Applicant: ALZA CORPORATION [US/US]: 1900 Charleston Road, P.O. Box 7210, Mountain View, CA 94039-7210 (US).
- (72) Inventors: DONG, Liang, C.; 181 Leota Avenue, Sunnyvale, CA 94086 (US). ESPINAL, Steven, D.; 330 Sierra Vista Avenue, Apt. 8, Mountain View, CA 94043 (US). WONG, Patrick, S.-L.; 1533 Burlingame Avenue, Burlingame, CA 94010 (US). MAGRUDER, Paul, R.; 1233 Wasatch Drive, Mountain View, CA 94040 (US).
- (74) Agents: STONE, Steven, F. et al.; Alza Corporation, 1900 Charleston Road, P.O. Box 7210, Mountain View, CA 94039-7210 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:
— Without international search report and to be republished upon receipt of that report.

[Continued on next page]

(54) Title: ANTIVIRAL MEDICATION



(57) Abstract: A pharmaceutical composition comprising a liquid antiviral formulation is disclosed. Additionally, a dosage form and a method for administering an antiviral pharmaceutical composition are disclosed.

DOCID: <WO__0141742A2_1_>

ANTIVIRAL MEDICATION

Field of the Invention

This invention pertains to a pharmaceutical composition, dosage form, and a method of treatment. More particularly, the invention pertains to pharmaceutical composition comprising a liquid antiviral drug formulation (also referred to antiviral pharmaceutical composition); a sustained release oral dosage form comprising the antiviral pharmaceutical composition; and a method of treatment comprising administering the sustained release oral dosage form comprising the antiviral pharmaceutical composition.

Background of the Invention

A pressing need exists for antiviral medications. The need exists, for example, for antiviral medication for the management of the human immunodeficiency virus.

15 The human immunodeficiency virus (HIV) is a retrovirus, which is the etiological agent for acquired immune deficiency syndrome, (AIDS). The virus is transmitted generally by parenteral inoculation, and by intimate social contact. A majority of those now infected with the virus will develop the acquired immune deficiency syndrome in a follow up period, usually seven to ten years.

Intensive research efforts to develop medications that can lessen or block the development of serious clinical symptoms in HIV-infected patients have lead to the discovery of protease inhibitors. Protease inhibitors effect the life cycle of viruses, thus, they are used as antiviral medications. Protease inhibitors operate by effecting the cleavage of high-molecular-weight viral polyprotein precursors necessary for the assembly and morphogenesis of viruses (Clin Neurobiol Rev Vol 11, p. 614-627, (1998)). Protease inhibitors, also known as antiretroviral drugs, such as saquinavir, ritonavir, indinavir, nelfinavir and amprenavir, are used to treat patients infected with the human immunodeficiency virus (Clin Ther, Vol 19, No. 2, p. 187-214, (1997)).

There are serious problems associated with the use of currently available protease inhibitors. For example, protease inhibitors exhibit a potential for forming drug resistance-HIV mutates so they may lose their potency in the absence of

protection in an acceptable dosage form. Further, since many drugs require three or more doses a day, poor patient compliance can be a significant factor leading to drug resistance. The drug also can exhibit an intrinsic aggregation tendency at hydrated states, which dictates against incorporating the antiviral protease inhibitors into a controlled-sustained release dosage form. Additionally, protease inhibitors are solids with limited absorption and poor aqueous solubility. Thus, protease inhibitors have low bioavailability. These properties do not lend themselves for formulation into pharmaceutical compositions for delivery from dosage forms that are therapeutically acceptable.

Therefore, there is a need for dosage forms comprising antiviral drug formulations that deliver a therapeutically acceptable level of the antiviral drug at a controlled-sustained release rate to a patient in need of antiviral therapy. The demand exists for delivery means for gastrointestinal delivery of antiviral drug for preventing *in-situ* aggregation effects of the antiviral drug, and obtaining improved bioavailability of the antiviral drug, which is substantially independent of the variable environment of the gastrointestinal tract.

Summary of the Invention

The present invention pertains to a pharmaceutical composition comprising a liquid antiviral drug formulation (also referred to an antiviral pharmaceutical composition); a sustained release oral dosage form comprising the antiviral pharmaceutical composition; and a method of treatment comprising administering the sustained release oral dosage form comprising the antiviral pharmaceutical composition. The inventors herein have found, surprisingly, that a pharmaceutical composition comprising a liquid antiviral drug formulation is substantially free of *in-situ* aggregation effects of the antiviral drug. Additionally, the inventors have discovered that the antiviral pharmaceutical composition has several advantages: (1) the antiviral pharmaceutical composition has a high loading of the antiviral drug, with up to 60 wt% of the antiviral drug dose solubilized in the composition; (2) the antiviral pharmaceutical composition has substantially improved bioavailability of the antiviral drug; and (3) controlled sustained release of high doses, up to 300 mg, of the

antiviral drug substantially improves patient compliance and reduce the likelihood of drug resistance.

Antiviral drugs such as protease inhibitors are solids with limited absorption, poor aqueous solubility and low bioavailability. The antiviral pharmaceutical composition of the present invention provides a sustained release oral dosage form to deliver a therapeutically acceptable level of the antiviral drug to a patient in need thereof. Additionally, the antiviral pharmaceutical composition provides improved bioavailability of the antiviral drug and is substantially independent of the variable environment of the gastrointestinal tract.

Accordingly, in one embodiment, the invention is directed to a pharmaceutical composition comprising a liquid antiviral drug formulation in a sustained release dosage form, wherein the pharmaceutical composition is substantially free of *in-situ* aggregation effect of the antiviral drug, and provides substantially improved bioavailability of the antiviral drug. The dosage form is adapted to administer a therapeutically effective dose of the antiviral drug over a period of at least 4 hours after oral administration. The pharmaceutical composition comprises an antiviral drug solubilized in a solvent, a hydrogel and optionally an osmagent. In preferred embodiments, the antiviral drug is a protease inhibitor and the solvent is a non-ionic surfactant, with up to 60 wt% of the antiviral drug dose being dissolved in the pharmaceutical composition.

In an additional embodiment, the invention is directed to a sustained release oral dosage form comprising a pharmaceutical composition comprising the liquid antiviral drug formulation (also referred to antiviral pharmaceutical composition) described above, wherein the antiviral pharmaceutical composition is substantially free of *in-situ* aggregation effect of the antiviral drug and provides substantially improved bioavailability of the antiviral drug. The dosage form administers a therapeutically effective dose of the antiviral drug over a period of at least 4 hours after oral administration.

In additional embodiments, the invention is directed to a sustained release oral dosage form as described above comprising: (a) a wall defining a compartment, the wall comprising a semipermeable layer; (b) an expandable layer located within the compartment and in fluid communication with the semipermeable layer; (c) a capsule
5 located within the compartment and in direct or indirect contacting relationship with the expandable layer, the capsule comprising an antiviral pharmaceutical composition as described above; and (d) an exit orifice formed or formable in the dosage form extending from the external surface of the capsule to the environment of use, the semipermeable layer comprises a semipermeable polymer, and the expandable layer
10 comprises a hydrophilic polymer and optionally an osmotically effective compound and a lubricant. In preferred embodiments, the dosage form comprises a gelatin capsule.

In certain embodiments of the dosage form, the expandable layer is located within the capsule and is remote from the exit orifice, and a barrier layer located
15 within the capsule between the antiviral pharmaceutical composition and the expandable layer. In alternative embodiments of the dosage form, the expandable layer is located within the compartment between the capsule and the semipermeable layer, and a barrier layer located within the compartment between the capsule and the expandable layer.

20 Further, the invention is directed to a method of treating a condition in a subject responsive to antiviral medication, the method comprising orally administering to the subject a sustained release dosage form comprising an antiviral pharmaceutical composition as described above.

These and other embodiments of the present invention will readily occur to
25 those of ordinary skill in the art in view of the disclosure herein.

Brief Description of the Figures

Figure 1 illustrates the release patterns for two delivery systems provided by the invention.

30 Figure 2 illustrates the release profile of a liquid delivery system, for the antiviral ritonavir.

Detailed Description of the Invention

As used in this specification and the appended claims, the singular forms "a," "an" and "the" include plural references unless the content clearly dictates otherwise.

5 The term "aggregation effect of the antiviral drug" as used herein means the antiviral drug can cluster together but do not fuse. The terms "antiviral drug" and "antiviral medication" are used interchangeably herein. Aggregation is a scientific phenomenon that can lead to sedimentation that substantially prevents the absorption of the antiviral drug at a controlled-sustained rate over time. Sedimentation as used
10 herein denotes the formation of an insoluble aggregation that may settle by gravitation. The pharmaceutical composition comprising a liquid antiviral drug formulation as described herein provides a composition substantially free of *in-situ* aggregation effect, thus substantially improving the bioavailability of the antiviral drug.

15 The term "surfactant" as used herein denotes a surface-active substance that reduces the surface tension of water. In preferred embodiments, the surfactant is a liquid non-ionic surfactant or an edible oil.

 The terms "controlled release rate" and "controlled rate" are used interchangeably herein, and refer to the release or delivery of a drug, e.g., from a
20 dosage form, at a constant rate for maintaining a constant drug level in blood-plasma or in a tissue. Sustained-release as used herein denotes the release of drug over an extended period of time, including the time of gastrointestinal transit.

 The term "liquid antiviral drug formulation" as used herein refers to an antiviral drug solubilized in a solvent, the solvent comprising surfactants, oils or
25 mixtures thereof. The liquid formulation may exist as a self-emulsifying composition wherein the antiviral drug is solubilized or suspended in the surfactant or a lipophilic component, which when dispersed in an aqueous environment forms become micelles or an emulsion. The results of the liquid spreading over the surface of the drug avoids drug agglomeration, thus providing the pharmaceutical composition as described
30 herein which is substantially free of *in-situ* aggregation effect of the antiviral drug.

The term "pharmaceutical composition comprising a liquid antiviral formulation"; "an antiviral drug composition"; "an antiviral pharmaceutical composition"; and "a pharmaceutical composition" are used interchangeably herein.

The terms "protease inhibiting" and "protease inhibitor" as used
5 interchangeably herein, and refer generally to a drug that prevents the reproduction of the human immunodeficiency virus (HIV) in a patient. Protease inhibitors operate by blocking an enzyme of HIV called protease. With the protease blocked, the HIV virus can't mature to infect cells. Clinical studies of protease inhibitors have shown these
10 drugs can lower the viral load and raise T-cells.

1. Modes of Carrying Out the Invention

The present invention pertains to a pharmaceutical composition comprising a liquid antiviral drug formulation (also referred to as an antiviral pharmaceutical composition); a sustained release oral dosage form comprising the antiviral
15 pharmaceutical composition; and a method of treatment comprising administering the sustained release oral dosage form comprising the antiviral composition. The inventors herein have found, surprisingly, that a pharmaceutical composition comprising a liquid antiviral drug formulation is substantially free of *in-situ* aggregation effects of the antiviral drug. Additionally, the inventors have discovered
20 that the antiviral pharmaceutical composition has several advantages: (1) the antiviral pharmaceutical composition has a high loading of the antiviral drug, with up to 60 wt% of the antiviral drug dose solubilized in the composition; (2) the antiviral pharmaceutical composition provides substantially improved bioavailability of the antiviral drug; and (3) controlled sustained release of high doses, up to 300 mg, of the
25 antiviral drug substantially improves patient compliance and reduce the likelihood of drug resistance.

Antiviral drugs such as protease inhibitors are solids with limited absorption, poor aqueous solubility and low bioavailability. The pharmaceutical composition comprising the liquid antiviral drug formulation of the present invention provides a
30 sustained release oral dosage form to deliver a therapeutically acceptable level of the antiviral drug to a patient in need thereof. Additionally, the antiviral pharmaceutical

composition provides improved bioavailability of the antiviral drug and is substantially independent of the variable environment of the gastrointestinal tract.

Accordingly, in one aspect, the invention is directed to a pharmaceutical composition comprising a liquid antiviral drug formulation in a sustained release dosage form, wherein the antiviral pharmaceutical composition is substantially free of *in-situ* aggregation effect of the antiviral drug, and provides substantially improved bioavailability of the antiviral drug. The pharmaceutical composition comprises an antiviral drug solubilized in a solvent, a hydrogel and optionally an osmagent and a lubricant.

10 The pharmaceutical composition comprises an antiviral drug in an amount of about 5 wt% to about 60 wt%; preferably about 5 wt% to about 55 wt%; and more preferably about 10 wt% to about 50 wt% of the total composition. Preferably, the antiviral drug formulation exists as a homogeneous blend, as a self-emulsifying formulation, as an emulsion or as micelles.

15 Examples of antiviral drugs include, but are not limited to acyclovir, azidouridine, anasmycin, amantadine, bromovinyldeoxusidine, chlorovinyldeoxusidine, cytarbine, didanosine, deoxynojirmycin, dideoxycytidine, dideoxyinosine, dideoxynucleoside, desciclovir, deoxyacyclovir, edoxuidine, enviroxime, fialuridine, fialuridine, fluorothymidine, fluxuridine, ganciclovir, hypericin, interferon, interleukin, isethionate, idoxuridine, nevirapine, 20 pentamidine, ribavirin, rimantadine, stavudine, surgramostin, suramin, trichosanthin, trifluorothymidine, tribromothymidine, trichlorothymidine, vidarabine, zidoviridine, zalcitabine and 3-azido-3-deoxythymidine.

Protease inhibitors inhibit human immunodeficiency virus (HIV) protease, the enzyme necessary for the maturation and the replication of the virus (Am J Health-Syst Pharm, Vol. 55, pp 233-254, (1998)). Examples of protease inhibitors include, but are not limited to, saquinavir, adefovir, ritonavir, indinavir, nelfinavir, amprenavir, zidovudine and zalcitabin.

30 The pharmaceutical composition comprises an antiviral drug solubilized in a solvent. The solvents comprise surfactants, oil, liophilic components and mixtures thereof. The pharmaceutical composition comprises a solvent in an amount of about

20 wt% to about 95 wt%; preferably about 20 wt% to about 80 wt%; more preferably about 30 wt% to about 70 wt%; and even more preferably about 40 wt% to about 60 wt% of the total pharmaceutical composition.

In preferred embodiments, the solvent is a liquid surfactant, more preferably a non-ionic surfactant. Examples of surfactants include, but are not limited to, polysorbates, i.e., polyoxyethylene sorbitan fatty acid esters, such as polyoxyethylene sorbitan monolaurate, wherein the number indicates the number of ethylene groups, polyoxyethylene 40 sorbitan monopalmitate, polyoxyethylene 60 sorbitan monostearate, and polyoxyethylene 80 sorbitan monooleate. The hydrophilic and lipophilic properties of polysorbates are useful for providing emulsions or micelles comprising antiviral drugs. The surfactants are known in Handbook of Pharmaceutical Excipients, edited by Wade and Weller, pp 375-378, (1994).

Examples of oils and lipophilic components for use as solvents in the pharmaceutical composition include, but are not limited to, superfine oils and triglycerides, such as almond oil, corn oil, cottonseed oil, menhaden oil, olive oil, orange roughy oil, peanut oil, safflower oil, sesame oil, shark liver oil, soybean oil, and the like; propylene glycol monoesters of fatty acids or glycerol fatty acid esters, such as capmuls, captexs, and the like; and distilled acetylated monoglycerides, such as myvacets, all of which are commercially available from Abitec, Croda or Eastman.

The pharmaceutical composition further comprises a hydrophilic polymer, such as, polyalkylene oxide, an alkali carboxyalkylcellulose, hydroxyalkylcellulose, hydroxypropylalkylcellulose, and the like. The pharmaceutical composition comprises a hydrophilic polymer in an amount of about 0 wt% to about 40 wt%; preferably about 0.1 wt% to about 30 wt%; and more preferably about 0.5 wt% to about 20 wt% of the total pharmaceutical composition.

Preferred hydrophilic polymers comprise polyalkylene oxide of 25,000 to 750,000 number average molecular weight. Preferably, the pharmaceutical composition comprises 5 wt% to 40 wt% of the polyalkylene oxide selected from the group consisting of polyethylene oxide of 50,000 to 325,000 molecular weight, polyethylene oxide of 400,000 to 650,000 molecular weight, and a polypropylene oxide of 75,000 to 300,000 molecular weight; and an alkali carboxyalkylcellulose of

- 25,000 to 750,000 number average molecular weight selected from the group consisting of poly(sodium carboxymethylcellulose), poly(potassium carboxymethylcellulose), poly(lithium carboxymethylcellulose), and poly(sodium carboxyethylcellulose). In additional embodiments, the pharmaceutical composition
- 5 comprises additionally 0 wt% to 20 wt% of a hydroxypropylalkylcellulose of 9,000 to 1,250,000 number average molecular weight. The hydroxypropylalkylcellulose prevents particles from agglomerating and inhibits the formation of drug sediments. Examples of hydroxypropylalkylcellulose include, but are not limited to, hydroxypropylmethylcellulose, hydroxypropylethylcellulose,
- 10 hydroxypropylbutylcellulose, and hydroxypropylpentylcellulose. In certain embodiments, the pharmaceutical composition comprises 0 wt% to 10 wt% of hydroxyalkylcellulose 10,000 to 1,150,000 number average molecular weight. Hydroxyalkylcellulose is used as a binder in the pharmaceutical composition. Examples of hydroxyalkylcellulose include, but are not limited to,
- 15 hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxybutylcellulose, and hydroxypentylcellulose.

- Additionally, the pharmaceutical composition comprises an osmagent. Osmagents are also referred to as osmotic solutes and osmotically effective agents, and are used interchangeably herein. The osmagents imbibe aqueous or biological
- 20 fluids into the pharmaceutical dosage form thereby dispensing the antiviral drug dissolved or dispersed in the surfactant or its mixture with an oil. The pharmaceutical composition comprises an osmagent in an amount of about 0 wt% to 25 wt%; preferably 0.1 wt% to 20 wt%; and more preferably 0.5 wt% to 20 wt% of the total pharmaceutical composition.

- 25 Examples of osmagents include, but are not limited to, sodium chloride, potassium chloride, lithium chloride, magnesium sulfate, magnesium chloride, potassium sulfate, sodium sulfate, lithium sulfate, potassium acid phosphate, sodium phosphate, mannitol, urea, inositol, magnesium succinate, tartaric acid, raffinose, sucrose, glucose, lactose, urea, carbohydrates, water soluble inorganic salts, and water
- 30 soluble organic salts. The osmotically effective solutes are known in U.S. Pat. No. 4,950,486.

Additionally, the pharmaceutical composition comprises a lubricant. The lubricant is used to enhance the manufacture of the pharmaceutical composition by lessening the incidence of ingredients adhering to manufacturing machinery. The pharmaceutical composition comprises a lubricant in an amount of about 0 wt% to 5 wt%; preferably 0.1 wt% to 5 wt%; and more preferably 0.5 wt% to 2 wt% of the total pharmaceutical composition. Examples of lubricants include, but are not limited to, magnesium stearate, calcium stearate, sodium stearate, stearic acid, glyceryl monostearate, glyceryl palmitostearate, zinc stearate, and talc. The total weight present, wt%, of all ingredients in the pharmaceutical composition is equal to 100 wt%.

In additional embodiments, the invention is directed to a sustained release oral dosage form comprising a pharmaceutical composition comprising the liquid antiviral drug formulation as described above, wherein the pharmaceutical composition is substantially free of *in-situ* aggregation effect of the antiviral drug and provides substantially improved bioavailability of the antiviral drug.

The sustained release oral dosage form comprises: (a) a wall defining a compartment, the wall comprising a semipermeable layer; (b) an expandable layer located within the compartment and in fluid communication with the semipermeable layer; (c) a capsule located within the compartment and in direct or indirect contacting relationship with the expandable layer, the capsule comprising the antiviral pharmaceutical composition as described above; and (d) an exit orifice formed or formable in the dosage form extending from the external surface of the capsule to the environment of use.

The pharmaceutical composition is manufactured into a dosage form by first adding the pharmaceutical composition to a capsule. The capsule can be classified according to conventional sizes including (000), (00), (0), (1), (2), (3), (4), and (5), wherein the diameter of the capsule is within the range of 10 mm to 3.0 mm. The inner capsule with the largest number has the smallest size. These capsules are disclosed in Microcapsule Processing and Technology, by Kondo and Van Vackenburg, page 2, (1979) published by Marcel Dekker, Inc. New York.

The capsule, in one manufacture, comprises two parts, a cap that slips over a body. The two parts are fitted together after the body is filled with the pharmaceutical composition. The assembly is done by slipping or telescoping the cap section over the body section, thereby completely surrounding and encapsulating the pharmaceutical composition. Capsules comprising a standard configuration are known in Pharmaceutical Sciences, by Remington, 14th ed., pp 1671-1677, (1970), published by Mack Publishing Co.

Capsules can also be classified as soft capsules and as hard capsules. The soft capsule, as used by the present invention preferably in its final form, comprises one piece. Generally, the soft capsule is of sealed construction encapsulating the antiviral pharmaceutical composition therein. The soft capsule is made by various processes including the plate process, the rotary die process, the reciprocating die process, and the continuous process. The plate process uses a set of molds. A warm sheet of prepared capsule-wall forming material is laid over a lower mold and the pharmaceutical composition poured on it. The second sheet of wall-forming material is placed over the pharmaceutical composition followed by the top mold. The mold is placed under a press and a pressure applied, with or without heat to form a unit, soft capsule member. The capsules are washed with a solvent for removing excess antiviral pharmaceutical composition from the exterior of the capsule and the air-dried capsule is capsuled with an expandable layer, also referred to as a hydroactivated layer, comprised of a hydroactivated composition.

A hard capsule is composed of two parts, a cap and a body, which are fitted together after the larger body is filled with a preselected appropriate antiviral pharmaceutical composition. This is done by slipping or telescoping the cap selection over the body section, thus completely surrounding and encapsulating the pharmaceutical composition. A hard capsule is made by dipping stainless steel molds into a bath containing solution of a capsule wall-forming material to coat the mold with the material. Then, the molds are withdrawn, cooled, and dried in a current of air. The capsule is stripped from the mold and trimmed to yield the capsule with an internal lumen. The engaging caps that telescopically caps the antiviral pharmaceutical composition receiving body is made in a similar manner.

Then, the closed and filled capsule is capsulated with an expandable layer comprised of a hydroactivated composition an outer semipermeable membrane. In another embodiment, the hard capsule can be made with each part having matched locked rings near the opened end that permits joining and locking together the overlapping cap and body after filling with the pharmaceutical composition. In certain embodiments, a pair of matched locking rings are formed into the cap portion and the body portion, and these rings provide the locking means for security holding together the capsule. The capsule can be manually filled or machine filled with the pharmaceutical composition. In the final manufacture, the hard capsule is capsulated with a semipermeable layer comprised of a semipermeable composition permeable to the passage of aqueous and biological fluids, and impermeable to the passage of ingredients contained in the capsule.

The rotary die process for providing a capsule comprises two continuous films of capsule wall-forming materials that are brought into convergence between a pair of revolving dies and an injector wedge. The process fills and seals the capsule in dual and coincident operations. In this process, the sheets of capsule forming compositions are fed over guide rolls, and then down between the wedge injector and the die rolls. The pharmaceutical composition to be capsulated flows by gravity into a positive displacement pump. The pump meters the pharmaceutical composition through the wedge injector and into the sheets between the die rolls. The bottom of the wedge contains small orifices lined-up with the die pickets of the die rolls. The capsule is about half-sealed when the pressure of pumped pharmaceutical composition forces the sheets into the die pockets. Wherein the soft capsules are simultaneously filled, shaped, hermetically sealed and cut from the sheets of wall-forming compositions. The sealing of the soft capsule is achieved by mechanical pressure on the die rolls and by heating the sheets of wall-forming compositions by the wedge. After manufacture, the antiviral pharmaceutical composition-filled capsules are dried in the presence of forced air.

The reciprocating die process produces soft capsules by leading two films of capsule wall-forming compositions between a set of vertical dies. The dies as they close, open, and close, perform as a continuous vertical place forming row after row

of pockets across the film. The pockets move through the dies, they are sealed, shaped and cut from the moving film as capsules filled with pharmaceutical composition. An expandable layer and a semipermcable layer are coated thereon to yield the osmotic dosage system. The continuous process is a manufacturing system
5 that also uses rotary dies with the added feature that the process can successfully fill an antiviral pharmaceutical composition into a soft capsule to encapsulating liquids therein.

The capsules, used for the purpose of this invention comprise a gelatin wall. The gelatin comprises a viscosity of 15 to 30 millipoises and a bloom strength up to
10 150 grams; gelatin having a bloom value of 160 to 250; a composition comprising gelatin, glycerine, water and colorant titanium dioxide; a composition comprising gelatin, erythrosin, iron oxide and titanium dioxide; a composition comprising gelatin, glycerine, sorbitol, potassium sorbate, and titanium dioxide; and a composition comprising gelatin, acacia, glycerine and water. Materials useful for forming capsules
15 are known in U.S. at. Nos. 4,627,850 and 4,663,148.

The capsule, in one manufacture provided by the invention is filled with the antiviral pharmaceutical composition and the capsule cap slid over the capsule body, then coated on its exterior surface with a semipermeable layer. The semipermcable layer form a membrane on the exterior surface of the capsule, and maintains its
20 physical and chemical integrity during operation of the dosage form and is essentially-free of interaction with the gelatin capsule.

The semipermeable membrane comprises a semipermeable polymer, including a semipermcable homopolymer and a semipermcable copolymer. In preferred embodiment, the semipermeable polymers comprise cellulose esters, cellulose ethers,
25 and cellulose ester-ethers. The cellulosic polymers have a degree of substitution. D.S. on their anhydroglucose unit from greater than 0 up to 3 inclusive. By degree of substitution is meant the average number of hydroxyl groups originally present on the anhydroglucose unit that are replaced by a substituting group, or converted into another group. The anhydroglucose unit can be partially or completely substituted
30 with groups such as acyl, alkanoyl, alkenoyl, aroyl, alkyl, alkoxy, halogen,

carboalkyl, alkylcarbamate, alkylcarbonate, alkylsulfonate, alkylsulfamate, semipermeable polymer forming groups, and the like.

Additional examples of semipermeable polymers include, but are not limited to, cellulose acylate, cellulose diacylate, cellulose triacylate, cellulose acetate, 5 cellulose diacetate, cellulose triacetate, mono, di- and tri-cellulose alkanylates, mono-, di-, and tri-alkenylates, mono-, di-, and tri-arylates, and the like. Exemplary polymers include cellulose acetate having a D.S. of 1.8 to 2.3 and an acetyl content of 32 to 39.9%; cellulose diacetate having a D.S. of 1 to 2 and an acetyl content of 21 to 35%, cellulose triacetate having a D.S. of 2 to 3 and an acetyl content of 34 to 44.8%, 10 and the like. More specific cellulosic polymers include cellulose propionate having a D.S. of 1.8 and a propionyl content of 38.5%; cellulose acetate propionate having an acetyl content of 1.5 to 7% and an acetyl content of 39 to 42%; cellulose acetate propionate having an acetyl content of 2.5 to 3%, an average propionyl content of 39.2 to 45%, and a hydroxyl content of 2.8 to 5.4%; cellulose acetate butyrate having 15 a D.S. of 1.8, an acetyl content of 13 to 15%, and a butyryl content of 34 to 39%; cellulose acetate butyrate having an acetyl content of 2 to 29%, a butyryl content of 17 to 53%, and a hydroxyl content of 0.5 to 4.7%; cellulose triacylates having a D.S. of 2.6 to 3 such as cellulose trivalerate, cellulose tripalmitate, cellulose tristearate, cellulose trioctanoate, and cellulose tripropionate; cellulose diesters having a D.S. of 2.2 to 2.6 such as cellulose disuccinate, cellulose dipalmitate, cellulose diotanoate, 20 cellulose dicarpylate, and the like; mixed cellulose esters such as cellulose acetate valerate, cellulose acetate succinate, cellulose propionate succinate, cellulose acetate octanoate, cellulose valerate palmitate, cellulose acetate heptonate, and the like. Semipermeable polymers are known in U.S. at. No. 4,077,407 and they can be 25 synthesized by procedures described in Encyclopedia of Polymer Science and Technology, Vol. 3, pages 325 to 354, 1964, published by Interscience Publishers, Inc. New York.

Additional semipermeable polymeric composition for forming a membrane that surrounds the capsule comprise cellulose acetaldehyde dimethyl acetate; cellulose 30 acetate ethylcarbamate; cellulose acetate methylcarbamate; cellulose dimethylaminoacetate; semipermeable polyamide; semipermeable polyurethanes;

semipermeable sulfonated polystyrenes; cross-linked selectively semipermeable polymers formed by the coprecipitation of a polyanion and a polycation as disclosed in U.S. Pat. Nos. 3,173,876; 3,276,586; 3,541,005; 3,541,006; and 3,546,142; semipermeable polymers as disclosed by Loeb et al in U.S. Pat. No. 3,133,132; 5 semipermeable poly (sodium styrenesulfonate); semipermeable poly (vinylbenzyltrimethylammonium chloride); semipermeable polymers, exhibiting a fluid permeability of 10^{-5} to 10^{-2} (cc. mil/cm hr.atm) expressed as per atmosphere of hydrostatic or osmotic pressure differences across a semipermeable wall. The polymers are known to the art in U.S. Pat. Nos. 3,845,770; 3,916,899, and 4,160,020 10 and in Handbook of Common Polymers, by Scott, J.R. and Roff, W.J., 1971, published by CRC Press, Cleveland, Ohio.

The dosage form comprises an expandable layer comprised of a hydroactivated composition. In certain embodiments of the dosage form, the expandable layer is located within the capsule and is remote from the exit orifice. The 15 pharmaceutical composition is added first into the body of the capsule. Then, the expandable layer is positioned in contact with the pharmaceutical composition followed by closing the capsule with the cap. The expandable layer is a push-displacement osmotic composition, and it operates to push and displace the pharmaceutical composition through an exit passageway from the dosage form. In 20 alternative embodiments of the dosage form, the expandable layer is located within the compartment between the capsule and the semipermeable layer. The expandable layer comprises hydrophilic polymers also known as hydrogels or osmopolymers. The osmopolymers exhibit fluid imbibition properties. The osmopolymers are swellable, hydrophilic polymers, which osmopolymers interact with water and 25 biological aqueous fluids and swell or expand. The osmopolymers exhibit the ability to swell in water and biological fluids and retain a significant portion of the imbibed fluid within the polymer structure. The osmopolymers swell or expand to a very high degree, usually exhibiting a 2 to 60 fold volume increase. The osmopolymers can be noncross-linked or cross-linked. The swellable, hydrophilic polymers are in one 30 presently preferred embodiment lightly cross-linked, such cross-links being formed by covalent or ionic bonds or residue crystalline regions after swelling.

The osmopolymers can be plant, animal or synthetic origin. The osmopolymers are hydrophilic polymers. Hydrophilic polymers suitable for the present purpose include poly (hydroxyalkyl-methoxyalkyl methacrylate) having a molecular weight of from 30,000 to 5,00,000; polyalkylene oxide of 1,500,000 to 10,000,000 number average molecular weight including polyethylene oxide of 5,000,000 molecular weight, and polyethylene oxide of 7,800,000 molecular weight; alkali carboxyalkylcellulose of 450,000 to 7,500,000 number average molecular weight represented by a member selected from the group consisting of sodium carboxymethylcellulose, potassium carboxymethylcellulose and lithium carboxymethylcellulose. The hydrogels comprise anionic and cationic hydrogels polyelectrolyte complexes; a mixture of methylcellulose, agar and sodium carboxymethylcellulose; a mixture of hydroxypropylmethylcellulose and sodium carboxymethylcellulose; a mixture of hydropropylethylcellulose and sodium carboxymethylcellulose; polyoxyethylene-polyoxypropylene gel; polyoxybutylene-polyethylene block copolymer gel; carob gum; polyacrylic gel; polyester gel; polyuria gel; polyether gel; polyamide gel; polycellulosic gel; polygum gel; initially dry hydrogels that imbibe and absorb water which penetrates the hydrogel and lowers its glass temperature; and the like.

Representative of other osmopolymers comprise polymers that form hydrogels such as Carbopol[®] acidic carboxypolymer, a polymer of acrylic and cross-linked with a polyallyl sucrose, also known as carboxypolymethylene and carboxyvinyl polymer having a molecular weight of 250,000 to 4,000,000. Cyanamer[®] polyacrylamides; cross-linked water swellable indenemaleic anhydride polymers; Good-rite[®] polyacrylic acid having a molecular weight of 80,000 to 200,000 polyethylene oxide polymers of 100,000 to 7,800,000 molecular weight blended with gums such as guar gum; starch graft copolymers; Aqua-Keps[®] acrylate polymer polysaccharide composed of condensed glucose units such as diester cross-linked polyglucanide; and the like. Representative polymers that form hydrogels are known to the prior art in U.S. Pat. No. 3,865,108 issued to Hartop; U.S. Pat. No. 4,002,173 issued to Manning; U.S. Pat. No. 4,207,893 issued to Michaels, and in Handbook of Common Polymers, by Scott and Roff, published by the Chemical Rubber Co., Cleveland, Ohio.

Additional examples of hydrophilic polymers comprise hydrophilic cellulose, such as, hydroxypropylmethylcellulose, hydroxypropylethylcellulose, hydroxypropylbutylcellulose and hydroxypropylpentylcellulose, the amount of the hydroxypropylalkylcellulose present in the push-displacement composition is 0 wt% to 25 wt%. The hydroxypropylalkylcellulose imparts cohesive qualities to a pharmaceutical composition or to the expandable layer. The expandable layer comprises a hydroxyalkylcellulose such as hydroxyalkylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxybutylcellulose, and hydroxyhexylcellulose. The amount of hydroxyalkylcellulose present in the expandable layer is 0 wt% to 15 wt%. The hydroxyalkylcellulose serves as a binder and as a stabilizing agent. The hydroxypropylcellulose are commercially available as Klucel EF of 80,000 molecular weight; Klucel® LF of 95,000 molecular weight; Klucel JF of 140,000 molecular weight; Klucel GF of 370,000 molecular weight; Klucel MF of 850,000 molecular weight; and Klucel HF of 1,150,000 molecular weight. The hydroxypropylcellulose are disclosed in Handbook of Pharmaceutical Excipients, 2nd ed., Edited by Wade and Weller, pp 223-228, (1994).

The expandable layer comprises a hydrophilic polymer in an amount of about 0 wt% to about 95 wt%; preferably about 10 wt% to about 70 wt%; more preferably about 25 wt% to about 70 wt%; and even more preferably about 50 wt% to about 70 wt% of the total composition of the expandable layer.

The expandable layer further comprises an osmotically effective compound comprising inorganic and organic compounds that exhibit an osmotic pressure gradient across the semipermeable membrane, against an external fluid. The osmotically effective compounds, as with the osmopolymers, imbibe fluid into the osmotic system, thereby making available displacement-push to push the pharmaceutical composition from the osmotic dosage form. The osmotically effective solutes are known also as osmagents and include, but are not limited to, magnesium sulfate, magnesium chloride, potassium sulfate, sodium sulfate, lithium sulfate, potassium acid phosphate, mannitol, urea, inositol, magnesium succinate, tartaric acid, carbohydrates, raffinose, sucrose, glucose, lactose, and sorbitol. Osmotically

effective solutes are taught in U.S. Pat. No. 4,783,337. The expandable layer
comprise an osmotically effective solute in an amount of about 0 wt% to about 60
wt%; preferably about 5 wt% to about 55 wt%; more preferably about 10 wt% to
about 40 wt%; and even more preferably about 20 wt% to about 30 wt% of the total
5 composition of the expandable layer.

The expandable layer optionally comprises a lubricant, which prevents or
reduces adhesion of the composition to the surfaces of dies and punches. The
lubricant comprises calcium stearate, zinc stearate, magnesium stearate, magnesium
oleate, calcium palmitate, sodium suberate, potassium laurate, stearic acid, salts of
10 fatty acids, salts of alicyclic acids, salts of aromatic acids, oleic acid, palmitic acid, and
a mixture of a salt of a fatty, alicyclic, or aromatic acid. The amount of lubricant in a
hydro-activated, push-displacement composition is 0.01 wt% to 4.5 wt%. The weight
of all ingredients in this composition is 100 wt%.

The pharmaceutical composition and the expandable layer can comprise 0
15 wt% to 3 wt% of a nontoxic colorant. The colorant makes the composition and the
composition more esthetic in appearance, and the colorant serves to identify the parts
of the dosage form during manufacture and therapy. The pharmaceutical composition
and the expandable layer comprise a different colorant. The colorants are represented
by FD&C Red No. 3; FD&C Red No. 40; FD&C Yellow No. 5; FD&C Yellow No. 6;
20 FD&C Blue No. 1; FD&C Blue No. 2; FD&C Green No. 3; iron oxide; and titanium
dioxide.

The expression "exit passageway" as used herein comprises means and
methods suitable for releasing the beneficial agent from the osmotic system. The
expression includes aperture, orifice, hole, bore, pore, porous element, porous
25 overlay, porous insert, hollow fiber, capillary tube, microporous insert, microporous
overlay, and the like. The passageway can be formed by mechanical drilling, laser
drilling, eroding an erodible element, extracting, dissolving, bursting, or leaching a
passageway former from the wall. The passageway can be a pore formed by leaching
sorbitol, lactose or the like from a wall or layer as disclosed in U.S. Pat. No.
30 4,200,098. This patent discloses pores of controlled-size porosity formed by
dissolving, extracting, or leaching a material from a wall, such as sorbitol from

cellulose acetate. The pore-passageways extend from the inside to the outside of a wall or layer for effective release of beneficial agent including a drug to the exterior of the osmotic system. U.S. Pat. No. 4,285,987 discloses an osmotic system comprising a first osmotic system comprising a cellulose acetate wall comprising leachable sorbitol for forming a pore for releasing an osmotically active beneficial agent from an osmotic core. This patent, discloses an osmotic system that exhibits drug released through a pore-passageway and drug released through a laser-drilled passageway within the total structure of the same osmotic system. Passageways are known in U.S. Pat. No. 4,783,337.

10 The dosage form is provided by coating a capsule with a semipermeable composition. The semipermeable composition can be applied to the exterior surface of the capsule by molding, spraying, dipping, or the like the capsule into a semipermeable coat-forming composition. Another technique that can be used for applying the semipermeable composition is the air suspension technique. This
15 technique consists in suspending and tumbling the composition in a current of air until the semipermeable composition surrounds and coats the capsule. The air suspension technique is described in U.S. Pat. No. 2,799,241: J. Am. Pharm. Assoc., Vol. 48, pp 451-459, 1979, and ibid, Vol. 49, pp 82-84, 1960. Other standard manufacturing procedures are described in Modern Plastic Encyclopedia, Vol. 46, pp 62-70, 1969,
20 and in Pharmaceutical Sciences, by Remington 14th Ed., pp 1626-1678, 1970, published by Mack Publishing Co., Easton, PA.

Representative of inorganic solvents and organic solvents for coating the capsule are solvents that do not adversely harm the materials, the capsule and the semipermeable coated capsule. The solvents broadly include members selected from
25 the group consisting of aqueous solvents, alcohols, ketones, esters, ethers, aliphatic hydrocarbons, halogenated solvents, cycloaliphatic, aromatics, heterocyclic solvents and mixtures thereof. Typical solvents include acetone, diacetone alcohol, methanol, ethanol, isopropyl alcohol, butyl alcohol, methyl acetate, ethyl acetate, isopropyl acetate, n-butyl acetate, methyl isobutyl ketone, methyl propyl ketone, n-hexane, n-
30 heptane, ethylene glycol monoethyl ether, ethylene glycol monoethyl acetate, methylene dichloride, ethylene dichloride, propylene dichloride, carbon tetrachloride,

- nitroethane, nitropropane, tetrachloroethane, ethyl ether, isopropyl ether, cyclohexane, cyclooctane, benzene, toluene, naphtha, 1,4-dioxane, tetrahydrofuran, diglyme, water, aqueous solvents containing inorganic salts such as sodium chloride acetone and water, acetone and methanol, acetone and ethyl alcohol, methylene dichloride and methanol, and ethylene dichloride and methanol.

- In alternative embodiments, the dosage form further comprises a barrier layer. In certain embodiments of the dosage form, the expandable layer is located within the capsule and is remote from the exit orifice, and the barrier layer is located within the capsule between the antiviral pharmaceutical composition and the expandable layer.
10. In alternative embodiments of the dosage form, the expandable layer is located within the compartment between the capsule and the semipermeable layer, and the barrier layer is located within the compartment between the capsule and the expandable layer.

- Suitable materials for forming the barrier layer may include, for example,
- 15 polyethylene, polystyrene, ethylene-vinyl acetate copolymers, polycaprolactone and Hytrel[®] polyester elastomers (Du Pont), cellulose acetate, cellulose acetate pseudolatex (such as described in U.S. Patent 5,024,842), cellulose acetate propionate, cellulose acetate butyrate, ethyl cellulose, ethyl cellulose pseudolatex (such as Surelease[®] as supplied by Colorcon, West Point, PA or Aquacoat[™] as supplied by
- 20 FMC Corporation, Philadelphia, PA), nitrocellulose, polylactic acid, polyglycolic acid, polylactide glycolide copolymers, collagen, polyvinyl alcohol, polyvinyl acetate, polyethylene vinylacetate, polyethylene terephthalate, polybutadiene styrene, polyisobutylene, polyisobutylene isoprene copolymer, polyvinyl chloride, polyvinylidene chloride-vinyl chloride copolymer, copolymers of acrylic acid and
- 25 methacrylic acid esters, copolymers of methylmethacrylate and ethylacrylate, latex of acrylate esters (such as Eudragit[®] supplied by RöhmPharma, Darmstadt, Germany), polypropylene, copolymers of propylene oxide and ethylene oxide, propylene oxide ethylene oxide block copolymers, ethylenevinyl alcohol copolymer, polysulfone, ethylene vinylalcohol copolymer, polyxylylenes, polyalkoxysilanes, polydimethyl
- 30 siloxane, polyethylene glycol-silicone elastomers, electromagnetic irradiation

crosslinked acrylics, silicones, or polyesters, thermally crosslinked acrylics, silicones, or polyesters, butadiene-styrene rubber, and blends of the above.

Preferred materials include cellulose acetate, copolymers of acrylic acid and methacrylic acid esters, copolymers of methylmethacrylate and ethylacrylate, and latex of acrylate esters. Preferred copolymers include poly (butyl methacrylate), (2-dimethylaminoethyl)methacrylate, methyl methacrylate) 1:2:1, 150,000, sold under the trademark EUDRAGIT E; poly (ethyl acrylate, methyl methacrylate) 2:1, 800,000, sold under the trademark EUDRAGIT NE 30 D; poly (methacrylic acid, methyl methacrylate) 1:1, 135,000, sold under the trademark EUDRAGIT L; poly (methacrylic acid, ethyl acrylate) 1:1, 250,000, sold under the trademark EUDRAGIT L; poly (methacrylic acid, methyl methacrylate) 1:2, 135,000, sold under the trademark EUDRAGIT S; poly (ethyl acrylate, methyl methacrylate, trimethylammonioethyl methacrylate chloride) 1:2:0.2, 150,000, sold under the trademark EUDRAGIT RL; poly (ethyl acrylate, methyl methacrylate, trimethylammonioethyl methacrylate chloride) 1:2:0.1, 150,000, sold as EUDRAGIT RS. In each case, the ratio x:y:z indicates the molar proportions of the monomer units and the last number is the number average molecular weight of the polymer.

Especially preferred are cellulose acetate containing plasticizers such as acetyl tributyl citrate and ethylacrylate methylmethacrylate copolymers such as Eudragit NE.

The foregoing materials for use as the barrier layer may be formulated with plasticizers to make the barrier layer suitably deformable such that the force exerted by the expandable layer 20 will collapse the compartment formed by the barrier layer 18 and gelatin capsule 12 to dispense the liquid, active agent formulation. Examples of typical plasticizers are as follows: polyhydric alcohols, triacetin, polyethylene glycol, glycerol, propylene glycol, acetate esters, glycerol triacetate, triethyl citrate, acetyl triethyl citrate, glycerides, acetylated monoglycerides, oils, mineral oil, castor oil and the like. The plasticizers may be blended into the material in amounts of 10-50 weight percent based on the weight of the material. The barrier layer and its composition is described in the international publication WO 00/35419, which is incorporated herein by reference.

In preferred embodiments, the sustained release oral dosage form comprises a gelatin capsule comprising a liquid antiviral drug composition which composition is substantially free of *in-situ* aggregation effect of the antiviral drug and substantially improved bioavailability of the antiviral drug; an exit orifice formed or formable in the dosage form extending from the external surface of the gelatin capsule to the environment of use; an expandable layer located within the capsule and remote from the exit orifice; a semipermeable layer surrounding the external surface of the capsule; and optionally a barrier layer located within the compartment between the capsule and the expandable layer.

In an alternative embodiment, the preferred sustained release oral dosage form comprises a gelatin capsule comprising a liquid antiviral drug composition which composition is substantially free of *in-situ* aggregation effect of the antiviral drug and substantially improved bioavailability of the antiviral drug; an expandable layer contacting the external surface of the gelatin capsule; a semipermeable layer surrounding the expandable layer; an exit orifice formed or formable in the dosage form extending from the external surface of the gelatin capsule to the environment of use; and optionally a barrier layer located within the capsule between the antiviral pharmaceutical composition and the expandable layer.

Methods Of Using The Invention

The invention pertains to a method for administering a beneficial protease inhibitor at a controlled rate to the gastrointestinal tract of a human. The method comprises: (A) admitting orally into the gastrointestinal tract a dosage form comprising: (1) a capsule comprising a single body or a capsule comprising a body and a matching cap telescopically joined to define a capsule comprising a lumen; (2) a pharmaceutical composition in the capsule comprising a protease inhibitor that is self-emulsified in the presence of a liquid nonionic surfactant; (3) a membrane that surrounds the capsule comprising a semipermeable polymer permeable to the passage of an aqueous or biological fluid, and impermeable to a protease inhibitor; and, (4) an exit passageway through the semipermeable membrane for delivering the protease inhibitor from the dosage form; and wherein the method comprises: (B) admitting

orally into the gastrointestinal tract a dosage form comprising: (1) a capsule comprising a single body, or a capsule comprising a body and a matching cap telescopically engaged to form a capsule comprising an internal lumen; (2) a pharmaceutical composition in the capsule comprising a protease inhibitor that is
5 solubilized or dispersed in a liquid nonionic surfactant or its mixture with a lipophilic component; (3) an osmotic layer in the capsule comprising a member selected from the group consisting of an osmopolymer and an osmagent; (4) a membrane that surrounds the capsule, the membrane comprising a semipermeable composition permeable to the passage of an aqueous or a biological fluid present in an
10 environment of use; (5) an orifice through the exterior membrane that communicates with the capsule; (C) imbibing fluid, in both dosage forms, through the semipermeable membrane into the capsule at a rate determined by the permeability of the semipermeable composition membrane, and the osmotic pressure gradient across the membrane thereby causing the pharmaceutical composition to be osmotically and
15 hydrodynamically pumped from the dosage form; and (D) delivering the protease inhibitor through the exit at a controlled-sustained rate to the patient over a prolonged period of time.

Another embodiment comprises a method of treating a condition in a subject responsive to antiviral medication, the method comprising orally administering to the
20 subject a sustained release dosage form comprising an antiviral pharmaceutical composition wherein the composition is substantially free of *in-situ* aggregation effect of the antiviral drug and provides substantially improved bioavailability of the antiviral drug. In preferred embodiments, dosage form administers a therapeutically effective dose of the antiviral drug over a period of at least 4 hours after oral
25 administration with no more than 30% by weight of the liquid composition being released within the first 1 hour after oral administration. In alternative embodiments, the dosage form administers a therapeutically effective dose of the antiviral drug over a period of at least 12 hours after oral administration with no more than 30% by weight of the liquid composition being released within the first 4 hours after oral
30 administration. In additional embodiments, the dosage form administers a therapeutically effective dose of the antiviral drug over a period of 24 hours after oral

administration with no more than 30% by weight of the liquid composition being released within the first 12 hours after oral administration. The dosage form produces an average steady-state plasma concentration of the antiviral drug greater than the therapeutically effective concentration of the antiviral drug over a period of between
5 about 4 hours to about 24 hours.

II. Experimental

Below are examples of specific embodiments for carrying out the present invention. The examples are offered for illustrative purposes only, and are not
10 intended to limit the scope of the present invention in any way, as these examples and other equivalents thereof will become more apparent to those versed in the art in the light of the present disclosure, the drawing figures and the accompanying claims.

Efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts, temperatures, etc.), but some experimental error and deviation should, of
15 course, be allowed for.

Example 1

A dosage for the controlled delivery of a liquid pharmaceutical composition is manufactured as follows: first, an osmotic push-displacement composition is
20 prepared using a fluid bed granulation. The osmagent sodium chloride is sized and screened in a mill using a 21-mesh screen. Then, the following dry ingredients are added into the granulation bowl: 58.75% sodium carboxymethylcellulose, 30% sodium chloride, 5.0% hydroxypropylmethylcellulose possessing an 11,200 number average molecular weight, and 1.0% colorant ferric oxide. All the ingredients are
25 blended in the granulator bowl. Next, in a separate container, a granulating solution is prepared by dissolving 5.0% hydroxypropylcellulose possessing an 80,000 molecular weight in purified water. Then, the granulating solution is sprayed onto the fluidized powders until all the granulating solutions is applied and the powders are granular. Then, 0.25% magnesium stearate lubricant is added to the granules and blended to
30 provide a homogenous composition. The granules are compressed into a tablet with a standard tableting press. Two hundred and fifty mg (milligrams) of the granules are

added to a 7.14 mm punch, tamped and then compressed under a force of 1 metric ton into a core.

Next, a pharmaceutical composition is prepared by homogeneously mixing 50 wt% nelfinavir and 50 wt% polyoxyethylene 20 sorbitan monooleate in a
5 homogenizer.

Then, a gelatin capsule, size 0, is separated into as body and cap sections. Next, 600 mg of the pharmaceutical composition comprising the antiviral nelfinavir is added to the capsule body. Then, the osmotic tablet, prepared above is placed at the top of the pharmaceutical composition. The filled capsule is closed with the capsule
10 cap.

Next, the assembled closed capsule is coated with a membrane on its exterior surface. The membrane possesses rate controlling properties and it assists in providing the controlled-sustained release dosage form. The membrane forming composition comprises 85% cellulose acetate having a 39.8% acetyl content, and 15%
15 polyoxypropylene glycol consisting of 14,600 molecular weight and 280 moles of ethylene oxide. The membrane forming ingredients is dissolved in acetone to provide a 4% solid solution. The solution is sprayed around the closed capsule in a standard coater to provide a membrane weighing 42 mg. The membrane coated capsules are dried at 40°C and ambient relative humidity over night to evaporate residual solvent.
20 Next, an exit passageway is drilled through the exterior membrane to provide a 15 mil (0.38 mm) passageway. The passageway connects the pharmaceutical composition with the environment of use.

The dosage form controlled-sustained release drug delivery profile is measured in artificial gastric fluid without enzyme. Accompanying Figure 1,
25 illustrates the cumulative amount of nelfinavir release from the liquid dosage form provided by this example and further identified by squares connected through a line for a 12 hour dosage form (system).

Example 2

The procedure of Example 1 is followed in this example, with all conditions as previously described, except in this example the membrane weighed 43 mg and comprised 70% cellulose acetate comprising an acetyl content of 39.8% and 30% polyoxypropylene glycol. The pharmaceutical composition weighed 600 mg and comprises 300 mg of nelfinavir. Accompanying Figure 1 shows 90% of the protease inhibitor is delivered in 4 hours at a constant rate, as seen with circles connected by a continuous line.

10.

Example 3

The procedure of Example 1 is followed in this example, with the manufacturing steps comprising fluid bed granulation to provide a push-displacement composition, compressing the freshly prepared composition into an osmotic layer that is sized, shaped and adapted for placing in a capsule, separately blending a protease inhibitor selected from the group consisting of saquinavir, adefovir, ritonavir, indinavir, nelfinavir, amprenavir, zidovudine and zalcitabin, with a non-ionic surfactant to provide a pharmaceutical composition, wherein in situ, the composition intakes an aqueous or a biological fluid causing the protease inhibitor to be solubilized in the nonionic surfactant, assembling the dosage form, by first adding the protease inhibitor nonionic surfactant composition, then placing the osmotic layer in the body of a capsule, capping the capsule, coating the closed capsule with a semipermeable membrane, and drying the coated capsule to remove residual solvent to provide the dosage form and then manufacturing an exit orifice in the dosage form.

25

Example 4

A dosage form for administering a protease inhibitor for treating a viral infection in a patient in need of a protease inhibitor therapy is prepared as follows: first, a pharmaceutical composition comprising 50 mg ritonavir, which is retrieved from a commercial product Norvir[®] capsule is filled into the body of a solution 0 size capsule. Then, an osmotic tablet, as described in Example 1, is placed on top of the pharmaceutical composition: next, the capsule closed is coated with a semipermeable

membrane, and an exit passageway formed in the semipermeable membrane. The membrane comprising 80% cellulose acetate containing 39% acetyl content and 20% Poloxamer[®] 338, a commercially available emulsifier, weighs 152 mg. The protease inhibitor is delivered from the dosage form at a controlled rate over 12 hrs (Fig. 2).

5

Example 5

A dosage form is manufactured according to claim 4, wherein 300 mg of a protease inhibitor selected from saquinavir, adefovir, ritonavir, indinavir, nelfinavir, amprenavir, zidovudine and zalcitabin is dispersed in a liquid carrier composed of a non-ionic surfactant and a mono-,di-triglyceride. Figure 2 illustrates a release profile for a delivery system provided by this invention.

10

Example 6

A dosage form is manufactured according to the procedure of Example 4, wherein in this example the liquid nonionic surfactant is a member selected from the group consisting of sorbitan monolaurate polyoxyethylene also known as Tween[®] 20; and sorbitan mono-oleate polyoxyethylene also known as Tween[®] 80. Cremophor EL a polyoxyethylene 35 castor oil, Cremophor RH, a glycerol polyethylenglycol oxystearate, or the mixture of the Cremophor with Labrasol, a saturated polyglycolized glyceride commercially available from Gattefossfe Inc., or the mixture of the Cremophors with Myvacet 945, an acetylated monoglyceride, commercially available from Eastman Chemical Co.

15

20

Example 7

A dosage form is manufactured according to the procedure of Example 4, with all conditions as set forth, except in this example the hydrogel is sodium carboxymethylcellulose of 40,000 number average molecular weight.

- 5 Accordingly, an antiviral pharmaceutical composition, a dosage form comprising the antiviral composition and a method of treatment are disclosed. Although preferred embodiments of the subject invention have been described in some detail, it is understood that obvious variations can be made without departing from the spirit and the scope of the invention as defined by the appended claims.

CLAIMS

We claim:

1. A sustained release oral dosage form comprising a liquid antiviral drug composition which composition is substantially free of *in-situ* aggregation effect of the antiviral drug and provides substantially improved bioavailability of said antiviral drug.
2. The dosage form of claim 1 which administers a therapeutically effective dose of said antiviral drug over a period of at least 4 hours after oral administration with no more than 30% by weight of said drug composition being released within the first 1 hour after oral administration.
3. The dosage form of claim 1 which administers a therapeutically effective dose of said antiviral drug over a period of at least 12 hours after oral administration with no more than 30% by weight of said drug composition being released within the first 4 hours after oral administration.
4. The dosage form of claim 1 which administers a therapeutically effective dose of said antiviral drug over a period of 24 hours after oral administration with no more than 30% by weight of said drug composition being released within the first 12 hours after oral administration.
5. The dosage form of claim 1 comprising:
 - (a) a wall defining a compartment, the wall comprising a semipermeable layer;
 - (b) an expandable layer located within the compartment and in fluid communication with the semipermeable layer;
 - (c) a capsule located within the compartment and in direct or indirect contacting relationship with the expandable layer, the capsule comprising said liquid antiviral drug composition; and

(d) an exit orifice formed or formable in the dosage form extending from the external surface of the capsule to the environment of use.

6. The dosage form of claim 5 wherein the expandable layer is located
5 within the capsule and is remote from the exit orifice.

7. The dosage form of claim 6 further comprising a barrier layer located within the capsule between the antiviral drug composition and the expandable layer.

10 8. The dosage form of claim 5 wherein the expandable layer is located within the compartment between the capsule and the semipermeable layer.

9. The dosage form of claim 8 further comprising a barrier layer located within the compartment between the capsule and the expandable layer.
15

10. The dosage form of claim 5 wherein said semipermeable layer comprises a semipermeable polymer; and the expandable layer comprises a hydrophilic polymer and optionally an osmotically effective compound.

20 11. The dosage form of claim 10 wherein the expandable layer further comprises a lubricant.

12. The dosage form of claim 11 wherein said hydrophilic polymer is present in the amount of about 0 wt% to about 95 wt%; the osmotically effective
25 agent is present in the amount of about 0 wt% to about 60 wt%; and the lubricant is present is about 0 wt% to about 5 wt% of the total composition of the expandable layer.

13. The dosage form of claim 1 wherein the liquid antiviral drug
30 composition comprises an antiviral drug solubilized in a solvent.

14. The dosage form of claim 13 wherein said solvent comprises a surfactant, an oil or mixtures thereof.

5 15. The dosage form of claim 14 wherein said surfactant is a non-ionic surfactant.

16. The dosage form of claim 14 wherein said liquid antiviral drug composition further comprises a hydrogel and optionally an osmagent.

10 17. The dosage form of claim 13 wherein said antiviral drug is present in an amount of about 5 wt% to about 60 wt% and the solvent is present in an amount of about 20 wt% to 95 wt% of the total antiviral drug composition.

15 18. The dosage form of claim 13 wherein the antiviral drug is selected from the group consisting of acyclovir, azidouridine, anasmycin, amantadine, bromovinyldeoxusidine, chlorovinyldeoxusidine, cytarbine, didanosine, deoxynojirmycin, dideoxycytidine, dideoxyinosine, dideoxynudeoside, desciclovir, deoxyacyclovir, edoxuidine, enviroxime, fiacitabine, foscarnet, fialuridine, fluorothymidine, fluxuridine, ganciclovir, hypericin, interferon, interlenkin,
20 isethionate, idoxuridine, nevirapine, pentamidine, ribavirin, rimantadine, stavirdine, sargramostin, suramin, trichosanthin, trifluorothymidine, tribromothymidine, trichlorothymidine, vidarabine, zidoviridine, zalcitabine and 3-azido-3-deoxythymidine.

25 19. The dosage form of claim 14 wherein said antiviral drug is a protease inhibitor.

20. The dosage form of claim 19 wherein said protease inhibitor is selected from the group consisting of saquinavir, adefovir, ritonavir, indinavir, nelfinavir,
30 amprenavir, zidovudine and zalcitabin.

21. A sustained release oral dosage form comprising a gelatin capsule comprising a liquid antiviral drug composition which composition is substantially free of *in-situ* aggregation effect of the antiviral drug and provides substantially improved bioavailability of said antiviral drug; an exit orifice formed or formable in the dosage
5 form extending from the external surface of the gelatin capsule to the environment of use; an expandable layer located within the capsule and remote from the exit orifice; a semipermeable layer surrounding the external surface of the capsule; and optionally a barrier layer located within the compartment between the capsule and the expandable layer.

10

22. A sustained release oral dosage form comprising a gelatin capsule comprising a liquid antiviral drug composition which composition is substantially free of *in-situ* aggregation effect of the antiviral drug and provides substantially improved bioavailability of said antiviral drug; an expandable layer contacting the external
15 surface of the gelatin capsule; a semipermeable layer surrounding the expandable layer; an exit orifice formed or formable in the dosage form extending from the external surface of the gelatin capsule to the environment of use; and optionally a barrier layer located within the capsule between the antiviral drug composition and the expandable layer.

20

23. The dosage form of claim 21 or claim 22 for use in treating a condition in a subject responsive to the antiviral drug, wherein said condition is acquired immune deficiency syndrome (AIDS) associated with human immunodeficiency virus (HIV) infection in the subject.

25

24. The dosage form of claim 23 which administers a therapeutically effective dose of said antiviral drug over a period of at least 4 hours after oral administration with no more than 30% by weight of said liquid composition being released within the first 1 hour after oral administration.

25. The dosage form of claim 23 which administers a therapeutically effective dose of said antiviral drug over a period of at least 12 hours after oral administration with no more than 30% by weight of said liquid composition being released within the first 4 hours after oral administration.

5

26. The dosage form of claim 23 which administers a therapeutically effective dose of said antiviral drug over a period of 24 hours after oral administration with no more than 30% by weight of said liquid composition being released within the first 12 hours after oral administration.

10

27. A pharmaceutical composition comprising a liquid antiviral drug formulation in a sustained release dosage form, wherein said composition is substantially free of *in-situ* aggregation effect of the antiviral drug and provides substantially improved bioavailability of said antiviral drug.

15

28. The pharmaceutical composition of claim 27 wherein the dosage form is adapted to administer a therapeutically effective dose of said antiviral drug over a period of at least 4 hours after oral administration with no more than 30% by weight of said liquid composition being released within the first 1 hour after oral administration.

20

29. The pharmaceutical composition of claim 27 wherein the dosage form is adapted to administer a therapeutically effective dose of said antiviral drug over a period of at least 12 hours after oral administration with no more than 30% by weight of said liquid composition being released within the first 4 hours after oral administration.

25

30. The pharmaceutical composition of claim 27 wherein the dosage form is adapted to administer a therapeutically effective dose of said antiviral drug over a period of 24 hours after oral administration with no more than 30% by weight of said liquid composition being released within the first 12 hours after oral administration.

30

31. The pharmaceutical composition of claim 23 wherein the liquid antiviral drug formulation comprises an antiviral drug solubilized in a solvent.

5 32. The pharmaceutical composition of claim 31 wherein said solvent comprises a surfactant, an oil or mixtures thereof.

33. The pharmaceutical composition of claim 32 wherein said surfactant is a non-ionic surfactant.

10

34. The pharmaceutical composition of claim 32 further comprising a hydrogel and optionally an osmagent.

35. The pharmaceutical composition of claim 33 wherein said antiviral
15 drug is present in an amount of about 5 wt% to about 60 wt% and the solvent is present in an amount of about 20 wt% to 95 wt% of the total antiviral drug composition.

36. The pharmaceutical composition of claim 31 wherein the antiviral drug
20 is selected from the group consisting of acyclovir, azidouridine, anasmycin, amantadine, bromovinyldeoxusidine, chlorovinyldeoxusidine, cytarbine, didanosine, deoxynojirmycin, dideoxycytidine, dideoxyinosine, dideoxynudeoside, desciclovir, deoxyacyclovir, edoxuidine, enviroxime, fiacitabine, foscarnet, fialuridine, fluorothymidine, fluxuridine, ganciclovir, hypericin, interferon, interlenkin,
25 isethionate, idoxuridine, nevirapine, pentamidine, ribavirin, rimantadine, stavirdine, sargramostin, suramin, trichosanthin, trifluorothymidine, tribromothymidine, trichlorothymidine, vidarabine, zidoviridine, zalcitabine and 3-azido-3-deoxythymidine.

30 37. The pharmaceutical composition of claim 32 wherein said antiviral drug is a protease inhibitor.

38. The pharmaceutical composition of claim 37 wherein said protease inhibitor is selected from the group consisting of saquinavir, adefovir, ritonavir, indinavir, nelfinavir, amprenavir, zidovudine and zalcitabin.

5

39. A method of treating a condition in a subject responsive to antiviral medication, the method comprising orally administering to the subject a sustained release dosage form comprising an antiviral drug composition wherein said composition is substantially free of *in-situ* aggregation effect of the antiviral drug and provides substantially improved bioavailability of said antiviral drug.

10

40. The method of claim 39 wherein said dosage form administers a therapeutically effective dose of said antiviral drug over a period of at least 4 hours after oral administration with no more than 30% by weight of said liquid composition being released within the first 1 hour after oral administration.

15

41. The method of claim 39 wherein said dosage form administers a therapeutically effective dose of said antiviral drug over a period of at least 12 hours after oral administration with no more than 30% by weight of said liquid composition being released within the first 4 hours after oral administration.

20

42. The method of claim 39 wherein said dosage form administers a therapeutically effective dose of said antiviral drug over a period of 24 hours after oral administration with no more than 30% by weight of said liquid composition being released within the first 12 hours after oral administration.

25

43. The method of claim 39 wherein said dosage form comprises a gelatin capsule comprising a liquid antiviral drug composition which composition is substantially free of *in-situ* aggregation effect of the antiviral drug and provides substantially improved bioavailability of said antiviral drug; an exit orifice formed or formable in the dosage form extending from the external surface of the gelatin capsule

30

to the environment of use; an expandable layer located within the capsule and remote from the exit orifice; a semipermeable layer surrounding the external surface of the capsule; and optionally a barrier layer located within the compartment between the capsule and the expandable layer.

5

44. The method of claim 39 wherein said dosage form comprises a gelatin capsule comprising a liquid antiviral drug composition which composition is substantially free of *in-situ* aggregation effect of the antiviral drug and provides substantially improved bioavailability of said antiviral drug; an expandable layer contacting the external surface of the gelatin capsule; a semipermeable layer surrounding the expandable layer; an exit orifice formed or formable in the dosage form extending from the external surface of the gelatin capsule to the environment of use; and optionally a barrier layer located within the capsule between the antiviral drug composition and the expandable layer.

15

45. The method of claim 43 or claim 44 wherein said dosage form produces an average steady-state plasma concentration of the antiviral drug greater than the therapeutically effective concentration of the antiviral drug over a period of about 4 hours to about 24 hours.

20

46. The method of any one of claims 39-44 wherein the antiviral drug composition comprises an antiviral drug solubilized in a solvent.

47. The method of claim 46 wherein said solvent comprises a surfactant, an oil or mixtures thereof.

25

48. The method of claim 47 wherein said surfactant is a non-ionic surfactant.

49. The method of claim 47 wherein said antiviral drug composition further comprises a hydrogel and optionally an osmagent.

30

50. The method of claim 46 wherein said antiviral drug is present in an amount of about 5 wt% to about 60 wt% and the solvent is present in an amount of about 20 wt% to 95 wt% of the total antiviral drug composition.

5

51. The method of claim 50 wherein said antiviral drug is a protease inhibitor.

52. The method of claim 51 wherein said protease inhibitor is selected from the group consisting of saquinavir, adefovir, ritonavir, indinavir, nelfinavir, amprenavir, zidovudine and zalcitabine.

10

1/2




FIGURE 1

2 / 2




FIGURE 2

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
14 June 2001 (14.06.2001)


PCT

(10) International Publication Number
WO 01/41742 A3

- (51) International Patent Classification²: A61K 9/22. A61P 31/18
- (21) International Application Number: PCT/US00/33542
- (22) International Filing Date: 8 December 2000 (08.12.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 60/169,883 9 December 1999 (09.12.1999) US
- (71) Applicant: ALZA CORPORATION [US/US]; 1900 Charleston Road, P.O. Box 7210, Mountain View, CA 94039-7210 (US).
- (72) Inventors: DONG, Liang, C.: 181 Leota Avenue, Sunnyvale, CA 94086 (US). ESPINAL, Steven, D.: 330 Sierra Vista Avenue, Apt. 8, Mountain View, CA 94043 (US). WONG, Patrick, S.-L.: 1533 Burlingame Avenue, Burlingame, CA 94010 (US). MAGRUDER, Paul, R.: 1233 Wasatch Drive, Mountain View, CA 94040 (US).
- (74) Agents: STONE, Steven, F. et al.: Alza Corporation, 1900 Charleston Road, P.O. Box 7210, Mountain View, CA 94039-7210 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:
— with international search report
- (88) Date of publication of the international search report:
14 February 2002

[Continued on next page]

(54) Title: ANTIVIRAL MEDICATION



(57) Abstract: A pharmaceutical composition comprising a liquid antiviral formulation is disclosed. Additionally, a dosage form and a method for administering an antiviral pharmaceutical composition are disclosed.

WO 01/41742 A3



For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/33542

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K9/22 A61P31/18

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 00 13674 A (ALZA CORP) 16 March 2000 (2000-03-16) example 8 page 7, line 27 -page 8, line 20 ---	1-7, 10-15, 17-19, 21, 23-33, 35-37, 39-43, 45-51
P,X	WO 00 35419 A (ALZA CORP) 22 June 2000 (2000-06-22) page 2, line 9 - line 13 page 29, line 21 -page 30, line 2 example 1 --- -/--	1-5, 8-10, 27-30, 39-42

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the international search

26 July 2001

Date of mailing of the international search report

07/08/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Epskamp, S

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/33542

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
P, X	WO 00 28942 A (HOFFMANN LA ROCHE) 25 May 2000 (2000-05-25) example	1-4, 13-17, 19, 20, 27-35, 37-42, 46-52
X	WO 98 22106 A (ABBOTT LAB) 28 May 1998 (1998-05-28) page 8, last paragraph -page 9, paragraph 1 page 10, paragraph 4 examples 4-39	1-4, 13-15, 17, 19, 20, 27-33, 35, 37-42, 46-48, 50-52
X	US 5 358 721 A (GUITTARD GEORGE V ET AL) 25 October 1994 (1994-10-25) examples 1,3 claims	39-42
A	US 5 830 502 A (FERRARI VINCENT J ET AL) 3 November 1998 (1998-11-03) column 5, line 50 - line 51 column 8, line 60 -column 9, line 21 claim 12	1-38
A	US 5 324 280 A (WONG PATRICK S L ET AL) 28 June 1994 (1994-06-28) example 1 claim 1	1-38

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Present claims 1-52 relate to compositions and methods relating to such compositions. that are defined by reference to desirable characteristics. namely:

- * "substantially free of in-situ aggregation effect of the antiviral drug" (claims 1, 21, 22, 27, 39, 43 and 44)
- * "provides substantially improved bioavailability of ... antiviral drug" (claims 1, 21, 22, 27, 39, 43 and 44)
- * "administers a therapeutically effective dose of ... antiviral drug over a period of at least x hours after oral administration with no more than 30% by weight of ... drug/liquid composition being released within y hours after oral administration" (claims 2-4, 24-26, 28-30, 40-42 and 45)

The claims cover all compositions having these characteristics. whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such compositions.

This lack of support and/or disclosure is further enhanced by the definition of certain antiviral drugs by their activity: "protease inhibitor" (claims 19, 20, 37, 38, 51, 52). This definition includes all (antiviral) active agents having this activity, whereas the application provides support and/or disclosure for only a very limited number of such compounds, namely those of claim 20 (note that according to the Merck index, 12th ed., zalcitabine and zidovudine are reverse transcriptase inhibitors, not (retroviral) protease inhibitors).

In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible.

Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the compositions by reference to a result to be achieved.

Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible.

Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the compositions defined in claims 5, in combination with the "protease inhibitors" as defined in claim 20 (as the problem solved by the application appears to be linked to problems associated with the use of currently available protease inhibitors, see description page 1, line 29 - page 2, line 9).

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/33542

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0013674	A	16-03-2000	AU 6136199 A EP 1117383 A	27-03-2000 25-07-2001
WO 0035419	A	22-06-2000	AU 2199400 A	03-07-2000
WO 0028942	A	25-05-2000	AU 1775100 A	05-06-2000
WO 9822106	A	28-05-1998	AU 717546 B AU 5257398 A BG 103425 A BR 9714310 A CN 1248914 A CZ 9901602 A EP 0942721 A HU 0002932 A JP 2000515555 T NO 992427 A PL 336980 A SK 65599 A	30-03-2000 10-06-1998 28-04-2000 02-05-2000 29-03-2000 11-08-1999 22-09-1999 29-01-2001 21-11-2000 20-07-1999 31-07-2000 10-12-1999
US 5358721	A	25-10-1994	NONE	
US 5830502	A	03-11-1998	US 5614578 A AU 695739 B AU 3966095 A AU 8612598 A CA 2200746 A EP 1057478 A EP 0782440 A JP 10508023 T NZ 295982 A WO 9613248 A ZA 9508892 A	25-03-1997 20-08-1998 23-05-1996 19-11-1998 09-05-1996 06-12-2000 09-07-1997 04-08-1998 27-05-1998 09-05-1996 05-07-1996
US 5324280	A	28-06-1994	AT 116543 T AU 645315 B AU 7673791 A CA 2039456 A DE 69106501 D DE 69106501 T DK 523172 T EP 0523172 A ES 2075444 T FI 924419 A IE 911040 A, B JP 2927956 B JP 7502252 T KR 176724 B NO 923756 A NZ 237642 A PT 97203 A, B WO 9115196 A US 5413572 A ZA 9102380 A	15-01-1995 13-01-1994 30-10-1991 03-10-1991 16-02-1995 11-05-1995 10-07-1995 20-01-1993 01-10-1995 01-10-1992 09-10-1991 28-07-1999 09-03-1995 20-03-1999 02-12-1992 27-07-1993 31-12-1991 17-10-1991 09-05-1995 29-01-1992